Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation
about
Evidence that BRCA1- or BRCA2-associated cancers are not inevitableDiet and risk of breast cancerThe KRAS-variant is associated with risk of developing double primary breast and ovarian cancerTo worry or not to worry: breast cancer genetic counseling communication with low-income Latina immigrantsBiomarker discovery and clinical proteomics.Hereditary and non-hereditary branches of family eligible for BRCA test: cancers in other sites.Ingredients for success: a familial cancer clinic in an oncology practice setting.Prospective study of high-risk, BRCA1/2-mutation negative women: the 'negative study'Development of cancer-initiating cells and immortalized cells with genomic instability.Genetic polymorphisms associated with breast cancer in malaysian cohortPredictors that Influence Election of Contralateral Prophylactic Mastectomy among Women with Ductal Carcinoma in Situ who are BRCA-Negative.Recognizing BRCA gene mutation risk subsequent to breast cancer diagnosis in southwestern OntarioChoices for young women at intermediate risk of breast cancerBRCA1 regulates follistatin function in ovarian cancer and human ovarian surface epithelial cells.Identifying post-menopausal women at elevated risk for epithelial ovarian cancerSEOM clinical guidelines in Hereditary Breast and ovarian cancer.BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study.Polygenic risk score is associated with increased disease risk in 52 Finnish breast cancer families.The Clinical Significance of Unknown Sequence Variants in BRCA Genes.The clinical utility of genetic testing in breast cancer kindreds: a prospective study in families without a demonstrable BRCA mutation.Folate and breast cancer: what about high-risk women?BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers?Emotional impact on the results of BRCA1 and BRCA2 genetic test: an observational retrospective study.Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2.Breast cancer in young women (YBC): prevalence of BRCA1/2 mutations and risk of secondary malignancies across diverse racial groups.BRCA1/2 negative status predicts no extended risk of invasive ovarian cancer.Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests.NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer.No evidence of excessive cancer screening in female noncarriers from BRCA1/2 mutation-positive families.Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel.Oral contraceptive use in women at increased risk of breast/ovarian cancer: knowledge and attitudes.Personalizing prophylactic surgery in cancer: current practice and future perspectives from new genome-wide association studies.Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families?Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer.
P2860
Q24600238-E5DB929D-BC6E-4EC1-BCCF-84D312AF5428Q26751985-E5545F78-09BA-48F8-AE82-005E61AC8DE1Q28729202-3DB03E98-AFC0-4ED1-ACDF-166939043C55Q30613390-59796574-84FC-4FD9-8B20-C94ECA45AC55Q33655101-D2FAC4F4-AA67-4D9B-87C9-22E9ED5BB0BBQ33730640-063FD709-BD68-4BBE-8BAA-49564BCBC2C0Q34459715-F60FCF18-082D-4E53-A30A-1DF4FF1B10DBQ35130901-8D568DAC-210B-4CDE-AB58-76297D330710Q35205699-B20FC661-1CB4-43AF-A79D-DE954AC858B0Q35365609-92E2B55C-CE12-4E82-AD90-BE3F8639134DQ35739522-C0B08F07-174D-4FFF-9901-16A441506CD2Q35962026-3AA2AE97-3A6F-48D9-939E-75FDBEB9D145Q36000212-CB980A36-F0AF-4AFB-9031-00B632902E6BQ36003520-BD76026F-BA99-4137-956B-08A1CF4C74EBQ36331643-F832C6FF-01FD-4654-8F36-A60B7E216E1BQ36400244-FD8B4034-8F3F-4BC5-AECE-C9ADAB8086B1Q36902674-11CEF88C-F6E1-486A-9B0E-431663B8D7D4Q37131918-78982208-8E35-4505-ABC6-F1E9859B3FE8Q37334266-F0433CE3-2F0F-42D4-B6D5-808D607A124AQ37656381-D404C76E-2686-4C77-8593-3C2AE885DF45Q38024316-11D636D4-1D5A-4A71-AB2A-565D07CC8C5AQ38417876-A7A07723-AA6F-4426-9456-30663B88669BQ41221895-81110648-0A53-4917-A082-EA21ADA32C69Q42260587-45180623-9A31-4371-B6A4-CB11AB6DA639Q43818565-D7A10E71-37C4-4B47-8550-9DF19BAC71DEQ43980686-19F27B70-5D24-4780-B048-007C4CB411DBQ44519692-8EC0EEA2-F689-47A9-AB4E-16991BBBA2EEQ46104940-80751F2A-9FEE-4B75-A710-057044AFBEECQ46782906-98D6A7E4-04EE-4D59-AE21-F039A988F703Q47154249-6AC79491-3805-4D0E-9690-5CB1CE9EA25FQ51352805-613EAF0C-8A18-423C-936E-705A016C6334Q51416016-228B1F85-3CEE-480D-BA89-BC06BC0B7E6CQ51698938-8D879630-AB80-4970-A8FA-522BFF9C6AE5Q52586080-F4ADF5E3-60CC-45B3-BF60-757FC7450FFCQ55437668-D2019FA8-7282-4174-9F7E-D28BADF16C58
P2860
Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Breast cancer risks in women w ...... for a BRCA1 or BRCA2 mutation
@en
Breast cancer risks in women w ...... for a BRCA1 or BRCA2 mutation.
@nl
type
label
Breast cancer risks in women w ...... for a BRCA1 or BRCA2 mutation
@en
Breast cancer risks in women w ...... for a BRCA1 or BRCA2 mutation.
@nl
prefLabel
Breast cancer risks in women w ...... for a BRCA1 or BRCA2 mutation
@en
Breast cancer risks in women w ...... for a BRCA1 or BRCA2 mutation.
@nl
P2093
P2860
P356
P1476
Breast cancer risks in women w ...... for a BRCA1 or BRCA2 mutation
@en
P2093
C Kim-Sing
K A Metcalfe
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604830
P407
P577
2008-12-16T00:00:00Z
P5875
P6179
1040036207